Using 'swallow-tail' sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson's disease: A susceptibility-weighted imaging study

Eur Radiol. 2017 Aug;27(8):3174-3180. doi: 10.1007/s00330-017-4743-x. Epub 2017 Jan 19.

Abstract

Objective: To investigate the value of 'swallow-tail' sign and putaminal hypointensity on 3 T susceptibility-weighted imaging (SWI) for distinguishing multiple system atrophy (MSA) from idiopathic Parkinson's disease (IPD).

Methods: Three groups - 39 MSA patients, 18 IPD patients,and 31 healthy controls (HCs) - were administered a 3 T SWI sequence to evaluate 'swallow-tail' sign and putaminal hypointensity using visual scales from 0 to 2 and 0 to 3 scores, respectively. The diagnostic accuracy of the two signs separately and combined was calculated using a receiver operating characteristic curve, with clinical diagnosis as the gold standard.

Results: The scores of 'swallow-tail' sign were lower in IPD than in MSA or in HCs, as well as for putaminal hypointensity in IPD or HCs than in MSA (p < 0.05). The sensitivity and specificity of 'swallow-tail' sign and putaminal hypointensity were 87.9% and 83.3%, and 35.9% and 100%, respectively, in the respective patient groups. The area under the curve of combined signs was increased from 0.85 ('swallow tail') or 0.68 (putaminal hypointensity) to 0.93.

Conclusion: The combination of 'swallow-tail' sign and putaminal hypointensity can increase the accuracy of discriminating between MSA and IPD.

Key points: • Differential diagnosis of MSA and IPD is still challenging in clinical practice. • Absence of 'swallow-tail' sign is a valuable biomarker for IPD on SWI. • Putaminal hypointensity is a valuable biomarker for MSA on SWI. • Combined 'swallow- tail' sign and putaminal hypointensity increase diagnostic accuracy.

Keywords: Idiopathic Parkinson’s disease; Multiple system atrophy; Putaminal hypointensity; Susceptibility-weighted imaging; Swallow tail.

MeSH terms

  • Aged
  • Analysis of Variance
  • Atrophy
  • Biomarkers
  • Case-Control Studies
  • Diagnosis, Differential
  • Female
  • Humans
  • Magnetic Resonance Imaging / methods*
  • Male
  • Middle Aged
  • Multiple System Atrophy / diagnosis
  • Parkinson Disease / diagnostic imaging*
  • Parkinson Disease / pathology
  • Putamen / diagnostic imaging*
  • ROC Curve
  • Sensitivity and Specificity
  • Substantia Nigra / diagnostic imaging*

Substances

  • Biomarkers